Kusajili – Clinical trials directory

phase II study of the combination of bevacizumab plus somatostatin analogue and metronomic capecitabine as first-line therapy in patients with advanced inoperable well-differentiated neuroendrocrine tumors To assess the antitumor activity in terms of objective response rate (RR) of bevacizumab in combination with somatostatin analogue and capecitabine administered on a metronomic schedule.

• Country None
• organs None
• Specialty None